Analytical Data
-
Gene name
PDGF-BB
- Application
-
Alternative Names
rHuPDGF-BB; PDGF-2; GDGF; ODGF; SIS; SSV
-
Species
Human
-
Source
E. coli
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01127-1
-
Expression Region
S82-T190
-
Protein Length
Partial
-
Molecular Weight
17 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Platelet-Derived Growth Factor-BB (PDGF-BB) is a crucial factor in various biological processes, particularly in cell proliferation, migration, and angiogenesis. It exists as a dimer formed by two PDGF-B chains and plays a significant role in wound healing and tissue repair. Research has shown that PDGF-BB is involved in the pathogenesis of several fibrotic diseases and cancers, highlighting its potential as a therapeutic target. The recombinant form of PDGF-BB has been extensively studied for its ability to stimulate osteogenesis and enhance vascularization in tissue engineering. By employing recombinant DNA technology, researchers can produce high-purity PDGF-BB, enabling detailed investigations into its biophysical properties and biological activities. Moreover, studies indicate that PDGF-BB can synergize with other growth factors to promote regenerative processes, making it a promising candidate for treating musculoskeletal injuries and chronic wounds. Understanding the molecular mechanisms underpinning PDGF-BB's actions can lead to the development of novel therapeutic strategies that harness its regenerative potential while minimizing adverse effects. As a result, PDGF-BB remains a focal point in regenerative medicine and biomaterial innovation, driving ongoing research towards optimizing its application in clinical settings.
